Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older

Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs GSK 1437173A (Primary) ; GSK 1437173A (Primary)
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms ZOSTER-032
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Dec 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-005671-14).
    • 21 Nov 2013 Planned End Date changed from 1 Jun 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top